Highlights in psoriatic arthritis from ACR 2024 include results of methotrexate added to DMARD therapy, responses to bimekizumab, and improvements gained by upadacitinib after prior TNF inhibitor use.
Following a prescribed medication regimen is vital to control rheumatoid arthritis symptoms. Disease-modifying antirheumatic drugs (DMARDs), biologics, and corticosteroids can help reduce inflammation ...